Nurix Therapeutics (Nasdaq:NRIX) - Prezzo delle azioni, notizie e analisi

NRIX Panoramica delle azioni

NRIX analisi fondamentale
Punteggio fiocco di neve
Valutazione	0/6
Crescita futura	2/6
Prestazioni passate	0/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Si prevede che i ricavi cresceranno 28.11% all'anno

Analisi del rischio

Si prevede che gli utili diminuiranno in media di 2.3% all'anno per i prossimi 3 anni

Gli azionisti sono stati diluiti nell'ultimo anno

Attualmente non redditizio e non si prevede che diventerà redditizio nei prossimi 3 anni

Nurix Therapeutics, Inc. Concorrenti

Deciphera Pharmaceuticals

NasdaqGS:DCPH

US$2.2b

BioCryst Pharmaceuticals

NasdaqGS:BCRX

US$1.7b

Twist Bioscience

NasdaqGS:TWST

US$2.4b

Veracyte

NasdaqGM:VCYT

US$2.6b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Nurix Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$24.58
Massimo di 52 settimane	US$27.60
Minimo di 52 settimane	US$4.96
Beta	2.22
1Variazione di 1 mese	11.88%
Variazione a 3 mesi	18.29%
Variazione di 1 anno	280.50%
3Variazione a 3 anni	-27.71%
Variazione a 5 anni	n/a
Variazione dall'IPO	29.30%

Notizie e aggiornamenti recenti

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31

Nurix: An Attractive Early-Stage Biotech Play

Oct 08

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Recent updates

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Oct 31

Nurix: An Attractive Early-Stage Biotech Play

Oct 08

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Sep 07

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Sep 04

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Jul 15

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Jun 19

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

May 29

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Apr 15

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Apr 14

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Feb 20

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Jan 16

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Dec 29

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Oct 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Oct 13

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Sep 30

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Apr 18

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Apr 15

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Nov 28

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Oct 06

Nurix Therapeutics GAAP EPS of -$1.01 misses by $0.02, revenue of $11.43M beats by $0.93M

Jul 07

FDA approves expansion of Nurix Therapeutics' phase 1 trial of NX-1607 into the U.S.

Jun 30

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

Jun 21

Rendimenti per gli azionisti

	NRIX	US Biotechs	US Mercato
7D	-6.4%	-1.3%	-1.6%
1Y	280.5%	19.1%	30.1%

Ritorno vs Industria: NRIX ha superato il US Biotechs che ha restituito 19.1 % nell'ultimo anno.

Rendimento vs Mercato: NRIX ha superato il mercato US che ha restituito 30.1 % nell'ultimo anno.

Volatilità dei prezzi

Is NRIX's price volatile compared to industry and market?
NRIX volatility
NRIX Average Weekly Movement	6.9%
Biotechs Industry Average Movement	9.6%
Market Average Movement	6.1%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.0%

Prezzo delle azioni stabile: NRIX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di NRIX è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
2009	284	Arthur Sands	www.nurixtx.com

Nurix Therapeutics, Inc. è una società biofarmaceutica in fase clinica che si concentra sulla scoperta, lo sviluppo e la commercializzazione di terapie cellulari e a base di piccole molecole per il trattamento di tumori, condizioni infiammatorie e altre malattie. L'azienda sviluppa NX-2127, un degradatore della tirosin-chinasi di Bruton (BTK) biodisponibile per via orale, per il trattamento dei tumori maligni a cellule B recidivati o refrattari; NX-5948, un degradante della BTK biodisponibile per via orale per il trattamento di tumori maligni a cellule B recidivati o refrattari e malattie autoimmuni; e NX-1607, un inibitore del proto-oncogene-B (CBL-B) del linfoma di lignaggio B Casitas biodisponibile per via orale per indicazioni di immuno-oncologia. Sta inoltre sviluppando NX-0479/GS-6791, un degradatore dell'IRAK4 per il trattamento dell'artrite reumatoide e di altre malattie infiammatorie.

Nurix Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Nurix Therapeutics con la sua capitalizzazione di mercato?
NRIX statistiche fondamentali
Capitalizzazione di mercato	US$1.74b
Guadagni(TTM)	-US$176.98m
Ricavi(TTM)	US$56.42m

30.9x

Rapporto P/S

-9.8x

Rapporto P/E

NRIX è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
NRIX Conto economico (TTM)
Ricavi	US$56.42m
Costo del fatturato	US$204.12m
Profitto lordo	-US$147.70m
Altre spese	US$29.28m
Guadagni	-US$176.98m

Ultimi guadagni dichiarati

Aug 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-2.50
Margine lordo	-261.76%
Margine di profitto netto	-313.65%
Rapporto debito/patrimonio netto	0%

Come si è comportato NRIX nel lungo periodo?

Vedi performance storica e confronto

NRIX Panoramica delle azioni

Premi

Analisi del rischio

Nurix Therapeutics, Inc. Concorrenti

NasdaqGS:DCPH

US$2.2b

NasdaqGS:BCRX

US$1.7b

NasdaqGS:TWST

US$2.4b

NasdaqGM:VCYT

US$2.6b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Nurix Therapeutics, Inc. Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics, Inc. Appoints Anil Kapur to Its Board of Directors

Nurix: An Attractive Early-Stage Biotech Play

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Recent updates

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Nurix Therapeutics, Inc. Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Nurix Therapeutics, Inc. Appoints Anil Kapur to Its Board of Directors

Nurix: An Attractive Early-Stage Biotech Play

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia At the European Hematology Association Congress

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

Nurix Therapeutics, Inc. Appoints Paula G. O’Connor as Chief Medical Officer and Pasit Phiasivongsa as Chief Technical Officer

Nurix Therapeutics Announces Board Chair Transition

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Reports First Clinical Evidence of CNS Activity of NX-5948, A Brain-Penetrant, Orally Available, BTK Degrader in Development for B Cell Malignancies

Nurix Therapeutics, Inc., Annual General Meeting, May 20, 2024

Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on Nx-2127 Phase 1 Trial

Price target decreased by 9.4% to US$24.09

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

Chief Financial Officer notifies of intention to sell stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics, Inc. Announces Publication in the Journal Science Identifying A New Class of Btk Mutations That Are Susceptible to Nx-2127, A Novel Btk and Ikzf1/3 Degrader

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Chief Financial Officer notifies of intention to sell stock

Nurix Therapeutics, Inc. Presents Positive Clinical Data from its Novel Bruton's Tyrosine Kinase (BTK) Degrader Programs, Nx-2127, at the 65th American Society of Hematology (ASH) Annual Meeting

Nurix Therapeutics, Inc. Announces Partial Clinical Hold for Nx-2127 Phase 1 Trial

New minor risk - Share price stability

Consensus revenue estimates increase by 21%

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

Third quarter 2023 earnings: EPS exceeds analyst expectations

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics, Inc. Plans to Initiate Two New Phase 1b Dose Expansion Cohorts in Ongoing Phase 1a/1b Clinical Trial of NX-2127 in Patients with Relapsed or Refractory B-Cell Malignancies

Consensus revenue estimates increase by 39%

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates decrease by 23%, EPS upgraded

Price target decreased by 7.7% to US$31.45

Full year 2022 earnings: EPS and revenues miss analyst expectations

Nurix Therapeutics Presents Positive Clinical Results from its Novel BTK Degrader (NX-2127) at the 64th American Society of Hematology (ASH) Annual Meeting

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Price target decreased to US$34.91

Nurix Announces Initial Nx-1607 Phase 1 Data Presented At the 37Th Annual Meeting of the Society for Immunotherapy of Cancer (Sitc) Demonstrating Targeted Cbl-B Inhibition in Patients with Advanced Malignancies

Nurix Therapeutics Inc. Reports Case Study of Patient with Aggressive Non-Hodgkin’s Lymphoma Showing a Complete Clinical Response to NX-2127 at the 5th Annual Targeted Protein Degradation Summit

Price target decreased to US$34.91

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Nurix Therapeutics GAAP EPS of -$0.90 beats by $0.07, revenue of $10.79M misses by $1.29M

Nurix Therapeutics, Inc. Appoints Edward C. Saltzman to its Board of Directors

Nurix Therapeutics, Inc. Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer

Price target decreased to US$38.20

Price target decreased to US$38.80

Nurix Therapeutics, Inc. has announced a Derivatives Offering in the amount of $54.996046 million.